Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: bocaburgerman who wrote (653)	2/11/1998 7:03:00 PM
From: seminole	Respond to of 1826

Winston While I can't tell you how much Canadian Sjorgren sales are included in these current results, I can give you an opinion that the number should be very small. The Sjorgren market and oncology market are independent. The Sjorgren market has completely different doctors/customers and will require time for market penetration through product marketing. I believe the company characterized the expected revenues from Salagen/Sjorgren sales as hockey stick like (Boy, can you tell their from Minn.). Slow initials sales before rapid, steady growth. They expect it will require three years to completely penetrate the Sjorgren market. They think european Salagen sales (15% royalties) will begin to contribte this year. richard